In glioblastoma patients who receive anti-survivin immunotherapy, the low levels of CD9 + /SVN + and CD9 + /GFAP + /SVN + exosomes have been correlated with the sustained patient's survival[77]. The gene discussed is CD9; the disease is glioblastoma.